Mayne Pharma's generic Quartette launches
Mayne Pharma has introduced its generic Quartette. The contraceptive product is a combination of levonorgestrel and ethinyl estradiol tablets, 0.15mg/0.02mg; 0.15mg/0.025mg; 0.15mg/0.03mg and ethinyl estradiol tablets, 0.01mg, and adds to the company's already existing 22 marketed women's health products.
"Mayne Pharma is the second largest supplier of oral contraceptive products in the United States and continues to invest in growing its pipeline of women's health products with high value, complex formulations such as generic NuvaRing, an intravaginal hormonal contraceptive delivery device which recently was accepted for filing by the FDA," Mayne Pharma CEO Scott Richards said
The Adelaide, Australia-based company's generic Quartette launches into a market that had estimated sales of roughly $10 million for the 12 months ended January 2018.
"Mayne Pharma is the second largest supplier of oral contraceptive products in the United States and continues to invest in growing its pipeline of women's health products with high value, complex formulations such as generic NuvaRing, an intravaginal hormonal contraceptive delivery device which recently was accepted for filing by the FDA," Mayne Pharma CEO Scott Richards said
The Adelaide, Australia-based company's generic Quartette launches into a market that had estimated sales of roughly $10 million for the 12 months ended January 2018.